Dr Susan Galbraith at ESMO 2014: The ‘National Lung Matrix’ trial – a new strategy for cancer drug research and development

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the National Lung Matrix trial, which is a collaboration between Cancer Research UK, AstraZeneca and Pfizer. This approach aims to improve the interaction between academia and industry, thereby facilitating the development of molecularly defined treatments in lung cancer.